Valuation: Xspray Pharma AB

Market Cap 800M 83.92M 72.95M 67.9M 62.34M 118M 8.01B 120M 314M 3.99B 315M 308M 13.37B P/E 2026 *
-2.72x
P/E 2027 * 5.12x
Enterprise Value 800M 83.92M 72.95M 67.9M 62.34M 118M 8.01B 120M 314M 3.99B 315M 308M 13.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
71.66%
Yield 2026 *
-
Yield 2027 * -
1 day+1.44%
1 week+10.62%
1 month+10.62%
3 months-36.66%
6 months-31.10%
Current year-46.33%
1 week 15.12
Extreme 15.12
17.1
1 month 14.56
Extreme 14.56
17.1
Current year 14.16
Extreme 14.16
32.5
1 year 14.16
Extreme 14.16
64.1
3 years 14.16
Extreme 14.16
91.7
5 years 14.16
Extreme 14.16
147.2
10 years 14.16
Extreme 14.16
267
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
Director of Finance/CFO 34 -
Chief Operating Officer 52 2024-05-31
Director TitleAgeSince
Director/Board Member 70 2014-12-31
Director/Board Member 52 2018-12-31
Chairman 72 2022-05-18
Date Insider Type Main position Quantity % Market Cap.
4/22/26 Sell

Director

4 0.0000%
4/22/26 Buy

Director

810 0.0019%
9/19/25 Buy

Director

2,063 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+10.62%-65.73%-50.21% 83.92M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average +0.03%-2.35%+25.71%+134.31% 23.39B
Weighted average by Cap. +0.23%-2.96%+30.76%+116.78%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Xspray Pharma AB
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Employees
24
Date Price Change Volume
26-07-31 SEK 16.88 +1.44% 26,364
26-07-30 SEK 16.64 -0.48% 28,969
26-07-29 SEK 16.72 +2.83% 56,836
26-07-28 SEK 16.26 +0.12% 67,148
26-07-27 SEK 16.24 +6.42% 101,244

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XSPRAY Stock